Windlas Biotech (Small Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Windlas Biotech Limited |
|||
|
Price: ₹820.80 (+0.94%) | ||
| 52 Week Low: ₹474.10 52 Week High: ₹1,198.25 |
|||
| Market Capital: 1,285.76 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Windlas Biotech Share Price Target For 2025
- 1.1.1: Windlas Biotech Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Windlas Biotech Share Price Target For 2026
- 1.2.1: Windlas Biotech Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Windlas Biotech Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Windlas Biotech Brief Company Overview
- 4: Windlas Biotech Financial Performance
- 4.0.1: Is Windlas Biotech A Good Buy For Long Term?
Windlas Biotech, a Small Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 248.2% returns in 3-year showing 35.5% quarterly revenue growth with 8.8% profit margin, making it a potential Multibagger.
To predict the Windlas Biotech's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Windlas Biotech Share Price Target For 2025
The line chart displays the monthly closing prices of Windlas Biotech with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Windlas Biotech shares in 2025, see the table below.
Windlas Biotech Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 951.0 (+15.86%) | Price Action: 25 Oct 2024 Low |
| 2025 Target 2 | 939.4 (+14.44%) | Price Action: 10 Oct 2024 High |
| 2025 Target 1 | 928.0 (+13.06%) | Price Action: 06 Sep 2024 High |
| Current Price | 820.80 | Windlas Biotech's share price as of 25 Feb 2025 |
| Stop Loss 1 | 770.2 (-6.17%) | Price Action: 19 Feb 2025 High |
| Stop Loss 2 | 760.35 (-7.37%) | Price Action: 24 Feb 2025 Low |
| Stop Loss 3 | 751.2 (-8.48%) | Price Action: 26 Jul 2024 High |
Short-Term Technical Outlook
Current Technical Position: Windlas Biotech is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹894.44 serves as the nearest technical reference point.
Historical Returns: 3-month: -24.91% | 6-month: +0.75% | 1-year: +64.06%
Windlas Biotech Share Price Target For 2026
The line chart displays the monthly closing prices of Windlas Biotech with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Windlas Biotech shares in 2026, see the table below.
Windlas Biotech Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 1465.57 (+78.55%) | Price Action: Chart |
| 2026 Target 2 | 1438.24 (+75.22%) | Fibonacci Extension Level 64.90% |
| 2026 Target 1 | 1422.77 (+73.33%) | Fibonacci Extension Level 123.60% |
| Current Price | 820.80 | Windlas Biotech's share price as of 25 Feb 2025 |
| Stop Loss 1 | 677.7 (-17.44%) | Price Action: 06 Jun 2024 High |
| Stop Loss 2 | 670.0 (-18.38%) | Price Action: 10 Jun 2024 High |
| Stop Loss 3 | 661.0 (-19.47%) | Price Action: 12 Jun 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Windlas Biotech is currently trading at 47.9% of its 52-week range (₹474.1 - ₹1198.25).
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: +64.06% | 3-year: +248.24% | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Windlas Biotech Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹820.80 | ||
| 2025 | ₹1,708.84 | +108.19% | ₹1,734.47 |
| 2026 | ₹2,522.48 | +47.61% | ₹2,560.32 |
| 2027 | ₹3,677.10 | +45.77% | ₹3,732.26 |
| 2028 | ₹5,342.97 | +45.3% | ₹5,423.11 |
| 2029 | ₹7,423.39 | +38.93% | ₹7,534.74 |
| 2030 | ₹9,403.23 | +26.67% | ₹9,544.28 |
| 2031 | ₹12,637.24 | +34.39% | ₹12,826.80 |
| 2032 | ₹16,258.27 | +28.65% | ₹16,502.14 |
| 2033 | ₹22,311.53 | +37.23% | ₹22,646.20 |
| 2034 | ₹28,364.45 | +27.12% | ₹28,789.92 |
| 2035 | ₹39,048.52 | +37.66% | ₹39,634.25 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Windlas Biotech Brief Company Overview
Windlas Biotech Limited: Leading CDMO Provider with a Comprehensive Product Range Founded in 2001, Windlas Biotech Limited is a renowned contract development and manufacturing organization (CDMO) based in Gurugram, India. The company offers a comprehensive...
suite of CDMO services, from product discovery to commercial manufacturing of generic products. Its diverse product portfolio includes tablets, capsules, pouches, sachets, liquid bottles, and a wide range of generic products, including fixed dosage combinations, modified release combinations, customized generics, and chewable or dispersible formulations. Windlas Biotech has established a strong reputation in the industry for its commitment to quality and innovation.Windlas Biotech Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 1,285.76 Crore | Market valuation of Windlas Biotech's shares. |
| Revenue (TTM) | 600.38 Crore | Total revenue generated by Windlas Biotech over the past twelve months. |
| Net Income (TTM) | +52.63 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +10.44% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +8.76% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+35.5% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+64.3% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
1.51 | Company's total debt divided by total shareholder equity. |
| Total Debt | 6.3 Crore | Sum of Windlas Biotech's current & long-term financial obligations. |
| Total Cash | 168.64 Crore | Total amount of liquid funds available to Windlas Biotech. |
| Beta | 0.49 | Beta is less than 1 indicating that the Windlas Biotech's price is less volatile than the market. |
Is Windlas Biotech A Good Buy For Long Term?
Windlas Biotech, a small-cap stock with a market cap of INR 1,285.76 Crore, exhibits promising financial performance. Over the last 12 months (TTM), it generated revenue of INR 600.38 Crore and net profit of INR 52.63 Crore. With an impressive profit margin of 8.76%, it has witnessed a 64.3% increase in earnings and 35.5% growth in revenue compared to the same quarter last year. While the company has a debt of INR 6.3 Crore, it maintains a healthy cash balance of INR 168.64 Crore. Given its strong financial position, consistent growth, and attractive returns in recent years, Windlas Biotech appears to be a promising investment for the long term.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
